NEXOBRID (Nexo Pharmaceuticals Pty Ltd)
Product name
NEXOBRID
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
208 (255 working days)
Active ingredients
anacaulase-bcdb
Registration type
NCE/ NBE
Indication
The approved indications for this therapeutic good are:
- NEXOBRID is indicated for eschar removal in adults and paediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.
- For further information on acceptable burn types, see Section 4.4 Special Warnings and Precautions.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.